Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Insulet Corporation is an innovative medical device company based in Acton, Massac...
Insulet Corporation is an innovative medical de...
Siemens Healthineers AG is the holding company of the Siemens Healthineers group. ...
Siemens Healthineers AG is the holding company ...
NanoVibronix Inc. is a medical device company that is focused on creating medical ...
NanoVibronix Inc. is a medical device company t...
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, dev...
Cytokinetics is a late-stage biopharmaceutical ...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
IDEAYA is an oncology-focused precision medicine company committed to the discover...
IDEAYA is an oncology-focused precision medicin...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.